Meitav Investment House’s PDS Biotechnology PDSB Stock Holding History

Meitav Investment House’s Portfolio PDSB Stock Details PDSB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1,200	Closed	-$28K	–	442
2018 Q1	$28K	Buy	+1,200	New	+$323K	﹤0.01%	335

Other funds holding PDSB

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Meitav Investment House's PDSB Position: Q2 2018 in Review

Meitav Investment House sold out of PDS Biotechnology (PDSB) in Q2 2018, closing a stake of 1,200 shares — an estimated $28K sold.

Meitav Investment House first reported a position in PDSB in Q1 2018 and held it in 1 quarter. The position peaked at $28K in Q1 2018. 43 funds tracked by Wall St. Rank hold PDSB as of Q2 2018.

Meitav Investment House reported no remaining PDS Biotechnology position as of Q2 2018 after selling out during the quarter.
Meitav Investment House sold 1,200 PDS Biotechnology shares in Q2 2018, an estimated $28K.
Meitav Investment House first reported a position in PDS Biotechnology in Q1 2018 and held it in 1 quarter.
Meitav Investment House's PDS Biotechnology position peaked at $28K in Q1 2018.
43 funds tracked by Wall St. Rank held PDS Biotechnology as of Q2 2018.

Based on Meitav Investment House's 13F filing for Q2 2018, filed 14 Aug 2018.